403
Sorry!!
Error! We're sorry, but the page you were looking for doesn't exist.
NKTR Stock Soars After Nektar Reports Positive Atopic Dermatitis Trial Results
(MENAFN- AsiaNet News)
Nektar Therapeutics Inc. (NKTR) shares rose more than 14% in Tuesday's pre-market trade after the company reported positive results from its long-term atopic dermatitis trial.
Nektar announced positive results from the 36-week blinded maintenance period of the 52-week REZOLVE-AD study of its experimental drug, rezpegaldesleukin.
Retail sentiment around Nektar Therapeutics trended in the 'extremely bullish' territory at the time of writing, with message volumes at 'extremely high' levels. The NKTR stock was among the top ten trending tickers on the platform.
Get updates to this story developing directly on Stocktwits.
For updates and corrections, email newsroom[at]stocktwits[dot]com.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research
More Story
Comments
No comment